
Stock·NYSE·Healthcare
Pfizer Inc. (PFE)
- Market cap
- $156.18B
- P/E
- 39.14
- Dividend yield
- 6.28%
- Street target
- $30.00median of 28 analysts
- 52-week range
- $23.62 $31.44
What moved Pfizer Inc. (PFE)
Updated . Market figures as of November 20, 2026.
Was it the market or the company?
On November 20, 2026, PFE fell 0.51%. The same day the S&P 500 (SPY) fell 3.64%, the Nasdaq 100 (QQQ) fell 5.67% and the health care sector (XLV) fell 0.12%.
The move was in line with the market. PFE's one-year beta to SPY is 0.28, so SPY's -3.64% would on average have meant -1.01% for PFE, close to what it did (0.5 percentage points less).
Over the last 20 sessions PFE is down 8.76% against -9.23% for SPY, 0.5 percentage points ahead of it.
The wider market on November 20, 2026: CNBC reported that the sell-off's breaking point came with Anthropic's initial public offering and heavier selling in Nvidia, which it named as the first of five forces behind the drop. (CNBC, November 20, 2026)
| That day | 5 sessions | 20 sessions | |
|---|---|---|---|
| PFE | -0.51% | -5.16% | -8.76% |
| S&P 500 (SPY) | -3.64% | -8.56% | -9.23% |
| Nasdaq 100 (QQQ) | -5.67% | -10.51% | -13.62% |
| Health care sector (XLV) | -0.12% | -6.15% | -1.14% |
Calculated by CleaRank from daily closes. Beta is measured on the last year of daily returns against SPY. A description of what happened, not a forecast.
What changed since November 19, 2026
- CleaRank score: 41/100 on November 19, 2026, 40/100 on November 20, 2026. The rating went from Hold to Sell.
PFE stock today, November 22, 2026: price, news and analyst targets
As of November 20, 2026, Pfizer Inc. (PFE) trades at $27.40. Wall Street's median 12-month price target is $30.00 across 28 analysts, 9.5% above the price. CleaRank rates it Sell with a score of 40/100.
Pfizer's stock is trading at $27.40, sitting between its 200-day average of $27.03 and its 50-day average of $28.82, and the CleaRank rating moved to Sell on November 20, 2026 as the score slipped to 40/100 from 41/100 the day before. The score had stood at 56/100 on November 16, 2026, so the drop over those days has been steady rather than sudden. The pressure comes mainly from momentum and valuation, with the stock below its shorter-term averages and trading at a premium to the sector on earnings. Analysts remain more constructive than the rating, with a median 12-month target of $30.00 and a consensus of Hold.
Why the rating moved to Sell
The CleaRank score has fallen across several sessions, from 56/100 on November 16, 2026 to 49/100 on November 17, 2026, to 43/100 on November 18, 2026, to 41/100 on November 19, 2026, and to 40/100 on November 20, 2026. The rating went from Hold to Sell on the last of those dates. The largest drags are momentum and valuation. The 14-day RSI is 32.5, in the bearish zone, and the MACD line is negative. The stock trades at a trailing P/E of 39.14, a premium to peers against a sector median of 31.9. The price-to-sales ratio of 2.45 sits 27.9% below the sector median of 3.4, so the premium is tied to earnings rather than sales.
Trend and the moving averages
The trend reading is mixed. The stock is 1.38% above its 200-day average but 4.93% below its 50-day average, and the 50-day average is 6.64% above the 200-day average. Over the past month the stock fell 8.21%, and over the past week it fell 5.16%. Over six months it is up 5.79% and over the year it is up 12.30%, so the longer-term direction remains positive even as the short-term picture has weakened.
Business and earnings backdrop
Revenue grew 2.60% in the latest quarter compared with the same quarter a year earlier, which is slower than the sector median growth of 8.1%. Net profit margin is 6.3% against an operating margin of 29.07%, and return on equity of 4.47% is below the sector median of 7.3%. The debt-to-equity ratio is 0.71. Analysts are more positive than the rating: of 28 analysts, 9 rate the stock buy or strong buy, 17 hold it and 2 sell it, and the median 12-month target is $30.00.
Dividend and insider activity
The trailing dividend yield is 6.28% on an annual dividend of $1.72 per share, a yield that is high for the sector and that supports the stock's appeal to income investors. Over the last 18 months insiders bought $3.0M of stock across three open-market purchases and sold $135K across two sales. Insider sales are often planned in advance or made to cover tax on vesting shares, so the open-market buying is the more telling signal of the two.
CleaRank score 40/100 (Sell). 9 of 18 checks pass: trend 2 of 4, momentum 1 of 3, valuation and quality 3 of 4, analysts 1 of 3, track record 2 of 4.
About Pfizer
Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines for people worldwide. Its current portfolio spans oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and hospital-based care, supported by a broad commercial network that serves physicians, hospitals, pharmacies, governments, and healthcare systems. Pfizer also maintains a consumer health presence through established over-the-counter and wellness products in select markets.
PFE stock news
Freedom Broker keeps Buy view
·Freedom Broker
Freedom Broker kept its Buy rating on November 7, 2026, one of two Buy reiterations from that firm in consecutive days. Repeated Buy ratings from a broker add to the analyst support that sits behind the $30.00 median target.
Second Freedom Broker Buy reiteration
·Freedom Broker
On November 6, 2026 Freedom Broker again kept its Buy rating on the stock. A second reiteration in two days shows the firm still sees upside from the current price.
Guggenheim keeps Buy rating
·Guggenheim
Guggenheim kept its Buy rating on November 5, 2026. The stock has a number of Buy ratings, but the broad split of 9 buy ratings against 17 holds shows that support is far from unanimous.
UBS holds Neutral stance
·UBS
UBS kept its Neutral rating on November 4, 2026. A neutral stance from a large broker matches the overall Hold consensus and gives no clear push in either direction.
Citigroup holds Neutral stance
·Citigroup
Citigroup kept its Neutral rating on November 4, 2026, alongside UBS. Two large brokers holding neutral views on the same day keeps the consensus anchored at Hold.
PFE price target 2026
The base case for the coming months is a stock that stays range-bound between its 200-day average and its 50-day average while the momentum readings stay weak. For the picture to improve, the price needs to reclaim the 50-day average at $28.82 and hold above the 20-day average, which would ease the bearish pressure on the trend factor. Analysts' median target of $30.00 sits above the price, and the highest target of $37.00 implies room if the company's revenue growth, which grew 2.60% year on year, begins to close the gap to the sector median of 8.1%. The downside case is a close below the 200-day average at $27.03, which would bring the 52-week low of $23.62 into view. Given the premium P/E of 39.14 against a sector median of 31.9, any slowdown in earnings would likely weigh on the valuation further. Recent insider buying of $3.0M across three purchases is a point in the stock's favour, though insider sales are often planned in advance and carry less weight.
Analyst targets and ratings
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 7, 2026 | Freedom Broker | Maintains | Buy |
| Nov 6, 2026 | Freedom Broker | Maintains | Buy |
| Nov 5, 2026 | Guggenheim | Maintains | Buy |
| Nov 4, 2026 | UBS | Maintains | Neutral |
| Nov 4, 2026 | Scotiabank | Maintains | Sector Outperform |
| Nov 4, 2026 | Citigroup | Maintains | Neutral |
PFE support and resistance levels
Support sits first at the 200-day simple moving average of $27.03, which the price is just above and which is the level a fall would meet first. Below that, the 52-week low of $23.62 marks the bottom of the stock's one-year range and the next level a sustained decline would reach. Resistance starts at the 50-day simple moving average of $28.82, which the stock fell back below on November 17, 2026. Just above it, the 20-day exponential moving average of $28.88 is the next barrier, and the 52-week high of $31.44 is the final level a rally would need to clear.
| Level | What it is | Price | From the price |
|---|---|---|---|
| Resistance 3 | 52-week high | $31.44 | +14.7% |
| Resistance 2 | 20-day exponential average | $28.88 | +5.4% |
| Resistance 1 | 50-day moving average | $28.82 | +5.2% |
| Price | November 20, 2026 | $27.40 | |
| Support 1 | 200-day moving average | $27.03 | -1.4% |
| Support 2 | 52-week low | $23.62 | -13.8% |
Technical indicators
PFE technical analysis in depth
Volatility, momentum, trend strength and the price levels that matter for PFE, calculated by CleaRank from daily bars to November 20, 2026.
Volatility
On the 20-day Bollinger Bands (2 standard deviations) the bands run from $27.48 to $31.15 around a middle of $29.32, and PFE's close of $27.40 sits below the lower band, a stretched reading.
Band width is 12.5% of the price, in the middle of its range over the last 120 sessions.
The 14-day average true range is $0.6728, or 2.5% of the price: a typical day's swing from high to low. A stop placed 1.5 ATR away would sit about 3.7% from the close.
Momentum and volume
The 14-day stochastic reads 1 (signal line 2): the close is near the bottom of its two-week range, an oversold zone.
The MACD line (12, 26) is -0.333 against a signal line (9) of -0.022, so the histogram is negative: momentum is weakening relative to its recent average. The MACD line crossed below its signal line 11 sessions ago.
Volume in the latest session was 1.0 times its 20-day average.
Trend strength
The 14-day ADX is 19, under 20: no strong trend in either direction, though sellers have the edge (+DI 20, -DI 26).
On the weekly chart the 10-week average ($28.82) is above the 40-week average ($27.00), a rising longer-term trend, and the weekly RSI is 49.
Key levels
The nearest resistance from the price history is $27.55 (+0.5%): the price turned here 6 times, most recently on October 5, 2026.
The nearest support is $26.52 (-3.2%): the price turned here 8 times, most recently on June 12, 2026.
The largest swing of the last 120 sessions ran up from $23.62 (June 25, 2026) to $31.44 (November 5, 2026); the nearest Fibonacci retracement to the price is the 50.0% level at $27.53.
Classic pivot points for the next session, from November 20, 2026: pivot $27.62, resistance $27.89 and $28.38, support $27.13 and $26.86.
| Level | Price | From the price | What it is |
|---|---|---|---|
| Upper Bollinger Band | $31.15 | +13.7% | 20-day average + 2 standard deviations |
| Fibonacci 23.6% | $29.59 | +8.0% | retracement of the rise from $23.62 to $31.44 |
| Resistance (swing high) | $29.03 | +6.0% | the price turned here 4 times, most recently on October 28, 2026 |
| Fibonacci 38.2% | $28.45 | +3.8% | retracement of the rise from $23.62 to $31.44 |
| Pivot R2 (classic) | $28.38 | +3.6% | next-session level |
| Resistance (swing high) | $28.14 | +2.7% | the price turned here 3 times, most recently on November 6, 2026 |
| Pivot R1 (Fibonacci) | $27.91 | +1.9% | 38.2% of the last range above the pivot |
| Pivot R1 (classic) | $27.89 | +1.8% | next-session level |
| Pivot point | $27.62 | +0.8% | average of the last high, low and close |
| Resistance (swing high) | $27.55 | +0.5% | the price turned here 6 times, most recently on October 5, 2026 |
| Fibonacci 50.0% | $27.53 | +0.5% | retracement of the rise from $23.62 to $31.44 |
| Lower Bollinger Band | $27.48 | +0.3% | 20-day average - 2 standard deviations |
| Price | $27.40 | close, November 20, 2026 | |
| Pivot S1 (Fibonacci) | $27.33 | -0.3% | 38.2% of the last range below the pivot |
| Pivot S1 (classic) | $27.13 | -1.0% | next-session level |
| Pivot S2 (classic) | $26.86 | -2.0% | next-session level |
| Fibonacci 61.8% | $26.61 | -2.9% | retracement of the rise from $23.62 to $31.44 |
| Support (swing low) | $26.52 | -3.2% | the price turned here 8 times, most recently on June 12, 2026 |
| Support (swing low) | $25.55 | -6.8% | the price turned here 4 times, most recently on July 17, 2026 |
| Fibonacci 78.6% | $25.29 | -7.7% | retracement of the rise from $23.62 to $31.44 |
| Support (swing low) | $24.84 | -9.3% | the price turned here 7 times, most recently on July 27, 2026 |
Swing levels are highs and lows the price turned at (the extreme of the five sessions either side), merged when they sit within 1.2 average true ranges of each other. Bollinger Bands (20, 2), ATR (14, Wilder), stochastic (14, 3), MACD (12, 26, 9), ADX (14, Wilder). Readings describe the chart; they are not a forecast.
PFE stock price and trading
PFE share price
PFE fundamentals and valuation
Key statistics
PFE against the Healthcare sector
Price to earnings vs sector: PFE trades at a significant premium to sector peers (+23% against the sector median P/E). Investors are paying more for each dollar of earnings than for the typical stock in the sector.
Return vs XLV: Since Jun 11, 2025, PFE has gained 11.9% against a gain of 30.6% for XLV.
Performance against XLV
Revenue and earnings
Revenue growth: Revenue fell 1.6% in FY2025 to $62.6B, from $63.6B a year earlier.
Profit margin: The net margin was 12.5% in FY2025, down from 12.7% the year before.
Profitable: PFE earned $7.8B in FY2025.
PFE price history and drawdowns
Risk profile
Worst falls and recoveries
Growth of $10,000
Against the market: PFE trailed the S&P 500 over this period: $14,444 against $36,764.
A $10,000 investment in PFE in December 2016 would be worth about $14,444 today with dividends reinvested, compared with about $36,764 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
PFE stock price prediction 2030
PFE Stock Price Prediction 2030: Simulated Scenarios
CleaRank's simulation projects a price near $30.44 for PFE by 2030 in the base case, from $27.40 today (1.1x over 4 years). The 10th-percentile path ends near $16.41. These are outcomes of a Monte Carlo simulation run on PFE's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $20.65 | $28.13 | $38.31 | |
| 2028 | $18.66 | $28.88 | $44.71 | |
| 2029 | $17.36 | $29.65 | $50.64 | |
| 2030 | $16.41 | $30.44 | $56.47 |
PFE insider trading
PFE insider trading
Month by month
Net insider buying: Insiders bought $3.0M on the open market and sold $135K.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 12, 2026 | Albert Bourla
Chief Executive Officer
|
Buy | 38.0K | $1.0M |
| Aug 5, 2026 | Jennifer B. Damico
Officer
|
Sell | 3.3K | $83.3K |
| Aug 5, 2026 | Ronald E Blaylock
Director
|
Buy | 39.2K | $998.8K |
| Aug 5, 2026 | Mortimer J. Buckley
Director
|
Buy | 37.6K | $960.4K |
| Jun 9, 2026 | Jennifer B. Damico
Officer
|
Sell | 2.0K | $51.4K |
| Mar 3, 2026 | Jennifer B. Damico
Officer
|
Grant | 21.7K | - |
| Feb 25, 2026 | Christoffel Boshoff
Officer
|
Grant | 13.4K | - |
| Feb 25, 2026 | Albert Bourla
Chief Executive Officer
|
Option | 491.6K | $16.6M |
| Feb 25, 2026 | Jennifer B. Damico
Officer
|
Option | 17.6K | $593.8K |
| Feb 25, 2026 | Lidia Fonseca, PH.D.
Officer
|
Option | 56.9K | $1.9M |
PFE stock forecast: questions people ask
PFE Forecast: Frequently Asked Questions
What is the PFE stock forecast?
What is the PFE price target?
Is PFE a buy or sell today?
Why is the P/E of PFE higher than the sector?
How has PFE performed over the past year?
Does PFE pay a dividend?
What does the recent insider activity show for PFE?
How these figures are computed, and where the data comes from: CleaRank methodology.